20.8 C
New York
Tuesday, September 27, 2022

Buy now


Lupin Inks Licensing Pact With Japan-Based I’rom Group

‘It can result in severe clinical consequences, such as back pain and bone fractures, particularly in the spine and hips. In progressing our development program for denosumab biosimilar, we hope to provide patients with early and expanded access to advanced biologic medicines, which have the potential to change their course of illness,’ he added.

Source link

Related Articles

Stay Connected

- Advertisement -spot_img

Latest Articles